The invention described herein relates to systems for monitoring patients, specifically those suffering from lymphedema, in both hospital and home environments.
Unless a term is expressly defined herein using the phrase “herein “______””, or a similar sentence, there is no intent to limit the meaning of that term beyond its plain or ordinary meaning. To the extent that any term is referred to in this document in a manner consistent with a single meaning, that is done for the sake of clarity only; it is not intended that such claim term be limited to that single meaning. Finally, unless a claim element is defined by reciting the word “means” and a function without the recital of any structure, it is not intended that the scope of any claim element be interpreted based on the application of 35 U.S.C. § 112(f).
The lymphatic system is a network of vessels primarily responsible for the collection and distribution of interstitial fluid throughout the body. The fluid that the lymphatic vessels carry—lymph—consisting of cellular waste products, proteins, peptides, and immune cells. When this vascular network is compromised, it is unable to drain and distribute fluid to the appropriate parts of the body. Consequently, unwanted lymphatic fluid buildup can lead to increased infection risk and severe swelling, giving rise to the condition known as lymphedema.
More specifically, lymphedema is a disease characterized by the accumulation of extracellular fluid or a buildup of adipose tissue in the interstitium due to reduced lymphatic transport in the setting of normal capillary filtration. Lymphedema is a chronic, incurable, progressive, and potentially debilitating condition, with numerous studies demonstrating notably reduced quality of life outcomes for those with chronic limb changes (Ahmed, R. L., et al. (2008). Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. Journal of Clinical Oncology, 26(35): p. 5689.; Penha, T. R. L., et al. (2016). Quality of Life in Patients with Breast Cancer—Related Lymphedema and Reconstructive Breast Surgery. Journal of reconstructive microsurgery, 32(06): p. 484-490.). Globally, lymphatic filariasis, a parasitic disease, causes lymphedema in over 120 million people in 72 countries. Development of lymphedema following a surgery or other medical intervention is commonly referred to as ‘secondary lymphedema.’ Although secondary lymphedema may arise due to infectious causes or cardiac, vascular, and renal impairment, most commonly secondary lymphedema develops after cancer surgery to remove lymph nodes, such as axillary lymph node dissection (herein “ALND”) in the breast cancer population. Depending on the number of lymph nodes removed, a patient's risk of lymphedema following ALND may be as high as 50% (Cemal, Y., Pusic, A., and Mehrara, B. (2011). Preventative Measures for Lymphedema: Separating Fact from Fiction. Journal of the American College of Surgeons, 213(4), 543-551. https://doi.org/10.1016/j.jamcollsurg.2011.07.001.). Furthermore, research in the last decade has demonstrated that the development of lymphedema is not limited to the breast cancer population alone. Lymphedema has been shown to be a well-known complication following treatment of melanoma, gynecologic cancer, genitourinary cancer, head, and neck cancer, sarcoma, radiation therapy, and pelvic dissection, with incidence ranging from 4-31% (Cormier, J. N., et al. (2010). Lymphedema beyond breast cancer. Cancer, 116, 5138-5149. https://doi.org/10.1002/cncr.25458.). While patients are at risk of developing lymphedema at any point in their life following cancer treatment, it is estimated that 80% of secondary lymphedema cases develop within the first two years following treatment and that 89% of all cases develop within the first three years following treatment (Norman, S. A., et al. (2009). Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. Journal of Clinical Oncology, 27(3): p. 390.).
The progression of lymphedema can be slowed or arrested using complete decongestive therapy (herein “CDT”), which typically consists of physiotherapy, compression, massage, and other techniques. Early intervention has been shown to have both outcomes and cost benefits (Shah, C., et al. (2016). The impact of early detection and intervention of breast cancer-related lymphedema: A systematic review. Cancer Medicine, 5(6), 1154-1162. https://doi.org/10.1002/cam4.691/.). Furthermore, current National Comprehensive Cancer Network (herein “NCCN”) guidelines on breast cancer recognize the importance of lymphedema as a possible complication of axillary lymph node surgery and recommend early diagnosis and intervention for lymphedema (National Comprehensive Cancer Network. Breast Cancer (Version 7.2021). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed Aug. 26, 2021.). For patients with breast cancer-related lymphedema, it has been estimated that without documented intervention, 48% of mild cases progress to the late stage of the disease, where limb changes become irreversible (Ad, V. B., et al. (2010). Time course of mild arm lymphedema after breast conservation treatment for early-stage breast cancer. International Journal of Radiation Oncology* Biology* Physics, 76(1): p. 85-90.).
Clinicians commonly rely on patient-reported symptoms of limb changes such as heaviness, tingling, or aching as the first sign that lymphedema may be present. The disease is then typically diagnosed using clinical exams and limb volume measurement or estimation. Common limb volume assessment methods include segmental circumference measurement, water volume displacement, and perometry, which uses infrared optical sensors to estimate limb volume. Complex radiologic imaging may also be performed to stage disease progressions, such as lymphoscintigraphy, magnetic resonance imaging, and computerized tomography. More recently, bioimpedance is an effective method of early diagnosis of lymphedema (Warren, A., Janz, B., Slavin, S. & Borud, L. (2007). The Use of Bioimpedance Analysis to Evaluate Lymphedema. Annals of Plastic Surgery, 58(5), 541-543. doi:10.1097/01.sap.0000244977.84130.cf.).
Bioimpedance analyzes tissue body-worn electrodes passing an alternating electrical current through a portion of the body to measure the impedance of current flow. This measurement technique operates on the principle that different tissues have different properties of resistance. For example, fat and bone act as insulators, while electrolytic fluids conduct electricity. In general, high-frequency currents pass through intracellular (herein “ICF”) and extracellular fluid (herein “ECF”), while low frequency currents are only able to pass through extracellular fluid. In this way, the impedance of intra- and extracellular fluid can be measured using the principle:
R
TOTAL
=R
ECF
+R
ICF
Where RTOTAL is the impedance measured through a tissue when a high-frequency current is applied, and RECF is the impedance measured through a tissue when a low-frequency current is applied. Subtracting RECF from RTOTAL yields RICF, which is the impedance corresponding to intracellular tissue. Since lymphatic fluid conducts electricity and accumulates in the extracellular space, its presence can be characterized by a drop in bioimpedance, particularly RECF.
Wearable bioimpedance sensors have been designed for cardiac indications (see, for example, U.S. Pat. No. 9,913,612, the contents of which are incorporated herein by reference). A primary example of this technology is Baxter's CoVa 2 Monitoring System, which has been FDA-cleared to measure cardiac output, stroke volume, chest fluid, heart rate, and other variables. CoVa 2 is a necklace-shaped device that attaches to a patient's chest with a pair of disposable electrodes. Using bioimpedance measures the parameters mentioned above and wirelessly transmits digitized numerical values and time-dependent waveforms to the cloud, where clinicians analyze them to diagnose the patient. Systems like these allow for patient monitoring in the home, which reduces the need for additional clinic visits. A wearable solution such as this could bring great value in the context of the lymphedema patient population, as these patients often have limited mobility and face a high number of clinic visits for oncologic and lymphedema treatment.
Despite significant work in the fields of lymphedema and fluid monitoring, there remains a need for a lymphedema-detection device that would allow patients or providers to take tissue property measurements quickly, reliably, easily, reproducibly, and quantitatively. Early detection of lymphedema allows for more prompt initiation of low-cost preventative therapies, leading to improved clinical outcomes and decreased cost to the patient and the healthcare system. There is a pressing need for a convenient and accurate method to detect lymphedema early in the disease progression, particularly before its progression to the second disease stage, when tissue changes become permanent. As there is no cure for lymphedema, the late-stage disease can only be managed using complete decongestive therapy, compression garments, and in some instances, microvascular surgical intervention—all these therapies at a high cost to the patient (Boyages J, et al. (2017). Financial cost of lymphedema borne by women with breast cancer. Psychooncology, 26(6):849-855. doi: 10.1002/pon.4239. Epub 2016 Aug. 21. PMID: 27479170.). Furthermore, without comprehensive knowledge about the fluid and fat composition of a patient's affected limb, the most appropriate surgical treatment cannot be prescribed. The lack of such a measurement for lymphedema progression limits the invention and adoption of novel treatment options which require clinical evidence. The only commercially available bioimpedance solution on the market, the SOZO device by Impedimed (see, for example, U.S. Pat. No. 10,653,334), is expensive, limited to in-office use only, and requires significant patient mobility to place hands and feet on the device for a measurement to occur.
In view of the foregoing, it would be beneficial to improve upon conventional approaches for generally measuring swelling and, more specifically, lymphedema in patients located in both the hospital and the home.
Given the above, in one aspect, the invention provides a system for characterizing fluids in a tissue located in a portion of a patient. The system features an impedance system that includes a current-injecting electrode that injects an electrical current into the portion of the patient, and a signal-measuring electrode that measures an impedance signal affected by the injected electrical current and an amount of the fluids. At least one of the electrodes includes an alignment feature that, during use, is aligned on the portion using a marking on the portion. The system also includes a processing system that receives the impedance signal from the impedance system, or a signal determined from it, and then processes the signal to determine a parameter related to the degree of fluids in the tissue.
The marking, for example, can be a permanent or semi-permanent marking, such as a tattoo. The tattoo can be a conventional tattoo used for medical purposes (e.g., radiation therapy for cancer), or alternatively a tattoo such as that described by Ephemeral Tattoo that has a limited lifetime, e.g., about one year. Alternately the tattoo could be comprised of a conductive material which matches to an electrical component of the alignment feature.
In embodiments, the alignment feature is one of an opening, optically transparent area, notch, or cut-out area configured to be disposed above the marking. The alignment feature is configured so that the marking can be visualized when the electrode containing the alignment feature is attached to the portion. In related embodiments, the alignment feature is a component configured to contact the patient proximal to the marking.
Typically, an external component that is remote from the patient includes the processing system, and is typically a hand-held component, e.g., a component mounted on the back surface of a mobile phone. It typically connects to the electrodes through a cable. In this and other embodiments, the hand-held component includes a wireless component, e.g., a Bluetooth® transceiver, a Wi-Fi transceiver, or a near field communication (herein “NFC”) tag from an NFC component. In related embodiments, the wireless transceiver may be a cellular modem operating on a cellular network that connects directly to the cloud. Typically, the hand-held component connects through the wireless or other means to an Internet-based component that receives information from the hand-held component. For example, the Internet-based component may be a system operating in the cloud (e.g., through Amazon Web Services) and features a web-based system with interfaces for both clinicians and the patient. The hand-held component may also include a mobile application that integrates to the Internet-based component.
In other embodiments, the processing system is worn directly on the patient's body. Here, the processing system is typically attached to the patient's body by one of the electrodes. In either case, the processing system typically operates a computer code that processes the impedance signal to determine the parameter related to the degree of fluids in the tissue. For example, the computer code can process a DC impedance signal (e.g., a change in this signal) to generate an index related to the degree of fluid build-up in the patient, e.g., the degree of lymphedema.
In preferred embodiments, the impedance system features two current-injecting electrodes and two signal-measuring electrodes. These electrodes typically include a hydrogel conductor that is matched to the electrical and mechanical impedance of the patient's skin. To this end, the impedance system typically features two electrode patches, with each electrode patch comprising one current-injecting electrode and one signal-measuring electrode.
In embodiments, the system features an electrical cable that connects the two electrode patches. For example, the electrical cable can be a stretchable cable, e.g., one that includes a conductor characterized by a resistance that changes with mechanical strain. Here, the conductor is typically coupled to a strain gauge. In related embodiments, the electrical conductor is in electrical contact with a distance-measuring component that generates a signal related to a degree that the stretchable cable stretches. For example, the distance-measuring component can include a capacitor characterized by a capacitance value that changes with the degree that the stretchable cable stretches. Alternatively, the distance-measuring component includes a resistor characterized by a resistance value that changes with the degree that the stretchable cable stretches. And in still other embodiments, the distance-measuring component is a piezoelectric material that generates a voltage that changes with the degree that the stretchable cable stretches.
In other embodiments, the system additionally includes an optical system featuring a light source and a photodetector. The light source is typically configured to irradiate the tissue located in the portion of a patient, and the photodetector is configured to detect radiation from the light source after it irradiates the tissue and, in response, generate a radiation-induced signal. Here, the processing system receives the radiation-induced signal, or a signal determined from it, and process it along with the impedance signal or a signal determined from it to determine the parameter related to the degree of fluids in the tissue in the portion of the patient. In related embodiments, the optical system features multiple light sources. For example, light sources of different wavelengths to examine the composition of the tissue and degree of fluids in the portion of a patient, e.g., amount of hemoglobin and deoxyhemoglobin. As another example, the light sources may be located at varying locations from the photodetector to obtain radiation-induced signals at multiple locations and/or depths in the portion of a patient. Alternatively, the optical system features multiple photodetectors. As an example, photodetectors at varying locations from a light source may generate radiation-induced signals at multiple locations and/or depths in the tissue in the portion of a patient. And in still other embodiments, the optical system features multiple light sources and photodetectors to obtain a combination of the above features.
In other embodiments, the system includes an electrocardiogram (herein “ECG”) system in electrical contact with the signal-measuring electrode that measures an ECG waveform. The processing system can process the ECG waveform to determine a value of heart rate (herein “HR”) corresponding to the patient.
In another aspect, the invention provides a system for characterizing fluids in a tissue located in a portion of a patient. The system includes an impedance system featuring at least one current-injecting electrode configured to inject an electrical current into the portion of the patient, and one signal-measuring electrode configured to measure an impedance signal affected by the electrical current and the fluids. The system also includes a distance-measuring system featuring a stretchable cable connected on one distal end to the current-injecting electrode, and at an opposing distal end to the signal-measuring electrode. The distance-measuring system generates an electrical signal that varies with a degree that the stretchable cable is stretched. The system also includes a processing system that receives the impedance signal from the impedance system and the electrical signal from the distance-measuring system, or signals determined therefrom, and collectively process them to determine an index related to an amount of fluids in the tissue in the portion of the patient.
In yet another aspect, the invention provides a system for characterizing fluids in a tissue located in a portion of a patient that includes an impedance measurement system similar to that described above, and a strain-measuring system comprising an electrical conductor coupled to the portion of the patient. The electrical conductor is characterized by an electrical resistance signal that varies with strain imparted on the electrical conductor by the fluids. A processing system receives the impedance signal from the impedance system and the electrical resistance signal from the strain-measuring system, or signals determined from these, and collectively processes them to determine an index related to the amount of fluids in the tissue in the portion of the patient.
And it yet another aspect, the invention contains any of the above-described systems embedded in a wearable cuff or sleeve. Such systems can also include methods of inflation (e.g., a pump) that serve two purposes: they force sensors within the cuff or sleeve to contact the patient's body and can also provide therapeutic compression to ameliorate the impact of lymphedema. Furthermore, the embedded sensors could be a combination of pressure sensors, e.g., piezoresistive or piezoelectric, or strain gauges.
In other embodiments, the system includes an electromyography (herein “EMG”) sensor, consisting of two measuring electrodes and a reference electrode, which measures electrical signals from muscle activation. Such EMG sensors can be used to evaluate swelling, inflammation, necrosis, and limb fat content.
In other embodiments, the circuit system also includes a motion sensor, such as an accelerometer or gyroscope. And in still other embodiments, the circuit system additionally consists of a flash memory system that stores digital representations of the signals. In other embodiments, the invention contains any of the above-described sensors embedded in a wearable ring for a finger or toe. For example, to measure an ECG or impedance waveform waveforms, the sensor would include an inner set of electrodes that contact a finger on the hand that the ring is worn and an outer set of electrodes that are contacted with fingers from the opposite hand. In a related embodiment, the invention includes any of the above-described systems embedded in a pair of glasses or spectacles. Here, for example, the sensors could be located on the pads for the bridge of the nose and behind the ears. In other embodiments, one of the sensors could be a flexible ultrasound system in a patch that adheres directly to the skin. Such a system could include electrodes made from polyimide, Cu, Cu/Sn, piezoelectric materials (e.g., pillars), and similar materials.
In light of the disclosure set forth herein, and without limiting the disclosure in any way, in a first aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, a system for characterizing fluids in a tissue located in a portion of a patient includes an impedance system and a processing system. The impedance system includes at least one current-injecting electrode configured to inject an electrical current into the portion of the patient, and at least one signal-measuring electrode configured to measure an impedance signal affected by the injected electrical current and an amount of the fluids. The system includes an alignment feature that during use is aligned on the portion using a marking on the portion. The processing system is configured to receive the impedance signal from the impedance system, or a signal determined therefrom, and then process it to determine a parameter related to the degree of fluids in the tissue.
In a second aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the alignment feature is one of an opening, optically transparent area, notch, or cut-out area configured to be disposed above the marking.
In a third aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the opening, optically transparent area, notch, or cut-out area is configured to allow the marking to be visualized when at least one of the current-injecting electrode and the signal-measuring electrode is attached to the portion.
In a fourth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the alignment feature is a component configured to contact the patient proximal to the marking.
In a fifth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the processing system is comprised by an external component that is remote from the patient.
In a sixth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the external component connects to at least one of the current-injecting electrode and the signal-measuring electrode through a cable.
In a seventh aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the external component is a hand-held component.
In an eighth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the hand-held component comprises a wireless component.
In a ninth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the wireless component comprises one of a Bluetooth® transceiver or a Wi-Fi transceiver.
In a tenth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the system further includes an Internet-based component configured to receive information from the hand-held component.
In an eleventh aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the processing system is configured to be worn on the patient's body.
In a twelfth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the processing system is attached to the patient's body by one of the current-injecting electrode and the signal-measuring electrode.
In a thirteenth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the processing system operates a computer code that processes the impedance signal to determine the parameter related to the degree of fluids in the tissue.
In a fourteenth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the computer code is configured to process a DC impedance signal.
In a fifteenth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the computer code is configured to process a change in the DC impedance signal.
In a sixteenth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the parameter is an index related to the change in the DC impedance signal.
In a seventeenth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the parameter indicates a degree of lymphedema in the patient.
In an eighteenth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the impedance system comprises two current-injecting electrodes and two signal-measuring electrodes.
In a nineteenth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the impedance system comprises two electrode patches, with each electrode patch comprising one current-injecting electrode and one signal-measuring electrode.
In a twentieth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the system further includes an electrical cable connecting the two electrode patches.
In a twenty-first aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the electrical cable is a stretchable cable.
In a twenty-second aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the electrical cable further comprises a conductor characterized by a resistance that changes with mechanical strain.
In a twenty-third aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the conductor is comprised by a strain gauge.
In a twenty-fourth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the electrical conductor is in electrical contact with a distance-measuring component that generates a signal related to a degree that the stretchable cable stretches.
In a twenty-fifth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the distance-measuring component comprises a capacitor characterized by a capacitance value that changes with the degree that the stretchable cable stretches.
In a twenty-sixth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the distance-measuring component comprises a resistor characterized by a resistance value that changes with the degree that the stretchable cable stretches.
In a twenty-seventh aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the distance-measuring component is a piezoelectric or piezoresistive material that generates a voltage that changes with the degree that the stretchable cable stretches.
In a twenty-eighth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the system further includes an optical system comprising a light source and a photodetector.
In a twenty-ninth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the light source is configured to irradiate the tissue located in the portion of a patient.
In a thirtieth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the photodetector is configured to detect radiation from the light source after it irradiates the tissue and, in response, generate a radiation-induced signal.
In a thirty-first aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the processing system is further configured to receive the radiation-induced signal, or a signal determined therefrom, and process it along with the impedance signal or a signal determined therefrom to determine the parameter related to the degree of fluids in the tissue in the portion of the patient.
In a thirty-second aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the system further includes an ECG system in electrical contact with the signal-measuring electrode and configured to measure an ECG waveform.
In a thirty-third aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the processing system is further configured to process the ECG waveform to determine a heart rate corresponding to the patient.
In a thirty-fourth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the system further includes an EMG system in electrical contact with the signal-measuring electrode and configured to measure EMG signals from muscle neurons in the patient.
In a thirty-fifth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the processing system is further configured to process the EMG signals to determine adipose tissue concentration corresponding to the patient.
In a thirty-sixth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the electrodes are embedded in a wearable cuff that is worn on an arm of the patient.
In a thirty-seventh aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, the system further includes a cuff comprising an inflatable mechanism that inflates the cuff and pushes the electrodes against the skin.
In a thirty-eighth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, a system for characterizing fluids in a tissue located in a portion of a patient includes an impedance system, a distance-measuring system, and a processing system. The impedance system includes at least one current-injecting electrode configured to inject an electrical current into the portion of the patient, and at least one signal-measuring electrode configured to measure an impedance signal affected by the electrical current and the fluids. The distance-measuring system includes a stretchable cable connected on one distal end to the at least one current-injecting electrode and at an opposing distal end to the at least one signal-measuring electrode. The distance-measuring system is configured to generate an electrical signal that varies with a degree that the stretchable cable is stretched. The processing system is configured to receive the impedance signal from the impedance system and the electrical signal from the distance-measuring system, or signals determined therefrom, and collectively process them to determine an index related to an amount of fluids in the tissue in the portion of the patient.
In a thirty-ninth aspect of the present disclosure, which may be combined with any other aspect, or portion thereof, a system for characterizing fluids in a tissue located in a portion of a patient includes an impedance system, a strain-measuring system, and a processing system. The impedance system includes at least one current-injecting electrode configured to inject an electrical current into the portion of the patient, and at least one signal-measuring electrode configured to measure an impedance signal affected by the electrical current and the fluids. The strain-measuring system includes an electrical conductor coupled to the portion of the patient, the electrical conductor characterized by an electrical resistance signal that varies with strain imparted on the electrical conductor by the fluids. The processing system is configured to receive the impedance signal from the impedance system and the electrical resistance signal from the strain-measuring system, or signals determined therefrom, and collectively process them to determine an index related to an amount of fluids in the tissue in the portion of the patient.
Additional features and advantages are described in, and will be apparent from, the following Detailed Description and the Figures. The features and advantages described herein are not all-inclusive and, in particular, many additional features and advantages will be apparent to one of ordinary skill in the art in view of the figures and description. Also, any particular embodiment does not have to have all of the advantages listed herein and it is expressly contemplated to claim individual advantageous embodiments separately. Moreover, it should be noted that the language used in the specification has been selected principally for readability and instructional purposes, and not to limit the scope of the inventive subject matter.
Although the following text sets forth a detailed description of numerous different embodiments, the legal scope of the invention described herein is defined by the words of the claims set forth at the end of this patent. The detailed description is to be construed as exemplary only; it does not describe every possible embodiment, as this would be impractical, if not impossible. One ordinary skill in the art could implement numerous alternate embodiments, which would still fall within the scope of the claims.
Referring to
To monitor this gradual swelling in the chest 5 (or any other portion of the body, such as the leg 2 and arm 4 in
The hand-held component 9 encloses a printed circuit board, such as that shown in
As lymphedema worsens in severity, the portion of tissue underneath the body-worn electrode patches 7a,b fills with fluid and swells. The increase in underlying fluid causes the resistance and impedance of the portion to change; the impedance circuit measures this. Concurrently the swelling increases the distance between the body-worn electrode patches 7a,b, which in turn increases the degree of stretching of the stretchable cable 11. This changes its resistance and/or capacitance, or the voltage it generates, as described above. The algorithm processes the digitized DC signals—which represent changes in impedance, resistance, capacitance, and/or voltage—to calculate a parameter related to the severity of the patient's lymphedema. A wireless transceiver within the hand-held device 9, e.g., a Bluetooth® or Wi-Fi transmitter, sends a digitized version of the parameter to a matched transceiver the patient's mobile phone 13, as indicated by the arrow 12. The mobile phone 13 then forwards the digitized version of the parameter to a cloud-based system 15, as indicated by the arrow 14. Typically, the cloud-based system 15 renders the parameter for both patients and clinicians or forwards the parameter (e.g., through a web services interface) to a third-party software application, such as a mobile application.
Similarly, as shown in
Alternatively, in place of or in addition to a variable resistor, a sensor 21 that measures strain can feature a variable capacitor. Here, the conductor 23a is replaced by a capacitor, which is typically a dielectric medium (e.g., plastic, glass, or polymeric material) covered on two opposing sides by thin, electrically isolated metal films. As the capacitor is stretched by swelling in the tissue, the thickness of the dielectric medium is reduced, and the metal films are drawn closer together. This reduces the capacitance of the system. A circuit that features this variable capacitor in series with a second capacitor having a known, fixed value can yield a voltage drop when biased. Measuring the voltage drop indicates the degree of strain in the system and, in turn, the degree of swelling in the underlying tissue.
As described above, in place or in addition to the variable resistor or capacitor described above, a sensor 21 may include a piezoelectric material that generates a voltage that varies with the degree that the conductor 23a is stretched.
Similarly, as indicated in
Alternatively, as shown in
Sensors are other than those shown in
Referring to
As shown in
Referring to
The circuit board 38 additionally includes sets of metal-plated holes that support a 4-pin connector 43, two 6-pin connectors 44, 45, and a 3-pin connector 46. More specifically, connector 43 connects directly to the pressure transducer, where it receives a common ground signal and analog impedance waveforms. These waveforms are filtered and digitized, as described in more detail below. Through connector 46 the circuit board receives power (+5V, +3.3V, and ground) from an external power supply, e.g., a battery or power supply located in the arm-worn housing. These power levels may be different in other embodiments of the invention. Digital signals and a corresponding ground from the analog-to-digital converter 39 are terminated at connector 45; they leave the circuit board 38 at this point, e.g., through cable segment 8 shown in
The circuit board 38 typically connects to the electronics module through a serial interface (e.g., SPI, I2C), which includes components for processing, storing, and transmitting data digitized by the analog-to-digital converter 39. For example, the electronics module typically includes a microprocessor, microcontroller, or similar integrated circuit. It can additionally provide analog and digital circuitry for other measurements, such as those indicated by the sensors shown in
In related embodiments, the electronics module can include both flash memory and random-access memory for storing time-dependent waveforms and numerical values, either before or after processing by the microprocessor. In still other embodiments, the circuit board can include NFC, Bluetooth®, Bluetooth Low Energy®, or Wi-Fi transceivers for both transmitting and receiving information.
The semi-permanent tattoo 54 is typically inscribed on the patient's skin 51 in a region above tissue inflicted with lymphedema. During use (typically, e.g., on a weekly basis) the electrode patch 47 is applied to the patient's skin 51 so that it is opening 50 is concentric with the circular semi-permanent tattoo 54, and its notch 52 is positioned directly proximal to the alignment feature 53 within the tattoo 54.
As shown in
57. For impedance measurements, the corresponding circuit typically injects alternating AC into the skin, wherein the frequency of the current typically varies from about 5 KHz to 500 KHz; in some embodiments, the circuit rapidly ‘sweeps’ the AC frequencies between these ranges.
Technically, the impedance measured with the circuit is a complex term, wherein electrical resistance encountered by the electrical current represents the real component of the impedance, and reactance encountered by the current represents the imaginary component of the impedance. More specifically to this particular measurement, impedance (the real component of the signal) is typically impacted by the volume of lymphedema-induced fluid, whereas reactance (the imaginary component of the signal) is typically impacted by the electrostatic storage of charge (i.e., capacitance) caused by the fluid.
On a more practical level, the above-described circuits process the bioelectric signals (e.g., filter and amplify them) to generate, respectively, analog time-dependent ECG, bioimpedance, and bio-reactance waveforms. These are then digitized with an analog-to-digital converter to yield digital waveforms suitable for follow-on processing.
Additionally, the circuit board 57 includes an optical sensor 62 that, in turn, features a light source 63 and a photodetector 64 operating in a reflection-mode geometry to determine optical properties (e.g., coloration, texture) of the patient's skin 51. During use, light source 63 irradiates a region of the patient's skin 51 disposed above the area of lymphedema. Radiation reflecting off the region will be impacted by conditions such as redness and mottling of the skin 51; the photodetector 64 senses the reflected radiation and generates a signal, which is then filtered and amplified by the corresponding circuitry on the circuit board 57 to generate a time-dependent ‘optical’ waveform. An algorithm (e.g., that shown in
During use, the electrode patch 47 is applied to the patient's skin 51 so that the opening 50 and the annular ring are concentric with the annular-shaped semi-permanent tattoo 54, and the patch's alignment feature 52 is proximal to the tattoo's alignment feature 53. If swelling is present, it may be necessary to stretch the patch 47 so that the tattoo 54 is entirely visible. This stretching, as described above, will induce strain in the strain gauges 55a-d. The device 65 featuring the above-described sensors then snaps into the electrode patch 47 so that electrical contacts 60a,b and 61a,b in electrical contact with an internal impedance circuit align with the different sets of sense 48a,b and drive 49a,b electrodes, and electrical contacts 58a-d align with the contacts 56a-d associated with the strain gauges. Note that all electrical contacts must be large enough to accommodate any stretching of the patch 47. With this process, the electrode patch 47 is consistently placed about the region of lymphedema, allowing repeatable measurements to be made using various circuits within the circuit board 57, as described above.
Typically, the electrode patch is composed of a foam substrate with an adhesive layer on its bottom surface. The sense 48a,b and drive 49a,b electrodes are typically made from a hydrogel material that is typically adhesive, electrically conductive and features an electrical impedance matched to the patient's skin. Electrical traces and contacts are typically composed of conductive materials, such as metal films or conductive ink. Electrodes may also be dry electrodes made of metals (e.g., tin, silver, sintered Ag/AgCl, gold, platinum, and stainless steel) or polymers (e.g., EDPM rubber with additives).
In related embodiments, a semi-permanent tattoo similar to that shown in
In a related embodiment, circuits used in the above-described sensors can be temporarily printed on the patient's body using conductive ink or electroconductive paint. Such a circuit may interface with an onboard microelectronic chip and be configured with sensors such as a strain gauge to determine the expansion of the limb and electrodes to assess limb fluid content using bioimpedance.
Steps 122-126 of this process are typically repeated on a somewhat periodic basis, e.g. every week, in order to help the patient keep their lymphedema under control. (Note: step 121, i.e. collecting the signals-baseline value, is only collected when the sensor is initially deployed.)
In other embodiments, the disposable electrodes (typically composed of a conductive hydrogel that contacts the patient and an adhesive foam backing) described above may be replaced by small ‘epidermal electrodes’ composed of conductive polymers that are printed directly on the patient's skin. Such epidermal electrodes feature several advantages over their disposable counterparts. They ensure consistent placement, reduce the burden on the patient to periodically apply disposable electrodes, and reduce skin irritation caused by the adhesive and hydrogel components within disposable electrodes. Epidermal electrodes provide a conductive interface with the patient's body through their skin. A conductive probe contacting them can detect electrophysiological signals that, once processed, yield time-dependent ECG and bioimpedance waveforms; as described above, further processing of these waveforms indicates early signs of lymphedema progression.
The conductive material used in epidermal electrodes may be drawn directly on the patient's skin with conductive ink. Alternatively, the electrode may be inkjet-printed onto standard tattoo paper and then transferred onto the skin in a similar fashion to a conventional press-on temporary tattoo. Such a system is referred to as the “electrode tattoo” in the following paper, the contents of which are incorporated herein by reference: Ferrari et al., 2020, the Institute of Solid State Physics, Graz, Austria. In this application, a system similar to that shown in
The patch 76 may also contain an optical system 115 featuring a light source 81a, such as an LED, and two photodetectors, 81b-c. In one embodiment, the combined light source 81a and photodetectors 81b,c measure the optical absorbance and/or reflectance of the skin and use these parameters to estimate the degree of swelling. In embodiments, for example, the optical system 115 is similar to that used in near-infrared spectroscopy (herein “NIRS”). With NIRS or any optical system used in the invention, the light source 81a emits optical radiation at multiple frequencies within the visible, ultraviolet, and/or infrared spectrum directly into the tissue portion. As the light travels through the tissue, photons are absorbed, reflected, and dispersed. Some photons will arrive to the photodetectors 81b,c and generate a signal (typically a time-dependent one) called a photoplethysmogram (herein “PPG”). Analysis of the properties of one or more PPGs can yield the composition of the underlying tissue as well as the concentration of certain molecules (e.g., Hb, HbO2, H2O, fat) therein. The concentration of these molecules is calculated according to the Beer-Lambert Law, where:
Absorbance (A)=Molar Attenuation Coefficient (ε)*Optical Path Length (L)*Concentration of Molecule (c)
In a typical embodiment, optical wavelengths in the 690-905 nm range can be used to measure Hb, HbO2, and melanin; longer wavelengths can be used to measure human fat content (e.g., 915 nm, 1210 nm, 1720 nm). Changes in oxygen perfusion and adipose tissue buildup relate to the progression of lymphedema due to swelling, inflammation, or necrosis. Melanin can be used to correct the absorption signals for patients of different skin tones.
The patch 76 also includes a temperature sensor 82 that measures temperature changes due to swelling in the portion of tissue underneath the patch. The temperature sensor 82 typically features a temperature-sensitive element (e.g., a thermocouple, temperature-sensitive resistor, thermopile, or thermal flow sensor) adhered to the surface of the skin. This particular measurement is predicated on the idea that swelling will cause the temperature of the portion of tissue and overlying skin to gradually increase. Bioelectric signals collected from the sensors 115, 119, 82 are then processed by a processor element 83, such as a microprocessor or microcontroller. As shown in
Alternatively, as shown in
In place of dye molecules, the injected tracer can be metal-based (e.g., Magtrace® iron nanoparticles available from www.mammotome.com/products/magtrace/), or a hypertonic fluid (e.g., 2-23% NaCl saline solution). In this case, as the tracer/ions travel through the patient's limb, the signal is measured by the sense electrodes normally used in the ECG/bioimpedance systems described above. Processor 87 can determine the concentration of the tracer based on the measured signals.
As shown in
Referring to
As shown in
Referring to
These and other embodiments of the invention are deemed to be within the scope of the following claims.
This application claims priority to and the benefit of U.S. Provisional Patent App. No. 63/327,956 filed Apr. 6, 2022, titled WIRELESS, INTERNET-BASED SYSTEM FOR MONITORING LYMPHEDEMA, the entire contents of which are incorporated by reference herein in their entirety and relied upon.
Number | Date | Country | |
---|---|---|---|
63327956 | Apr 2022 | US |